DryShips Inc. Announces Proposed Entry by Wholly Owned

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DryShips Inc. Announces Proposed Entry by Wholly Owned Subsidiaries of Ocean Rig UDW Inc. Into $1.3 Billion Term Loan Facility and Withdrawal of Proposed Offering of Senior Notes

ATHENS, GREECE--(Marketwired - Jul 18, 2014) - DryShips Inc. ( NASDAQ : DRYS ) (the "Company" or "DryShips"), a global provider of marine transportation services for drybulk and petroleum cargoes, and through its majority owned subsidiary, Ocean Rig UDW Inc. ("Ocean Rig"), of offshore deepwater drilling services, today announced that due to favorable loan market conditions, Ocean Rig's wholly owned subsidiaries, Drillships Ocean Ventures Inc. and Drillships Ventures Projects Inc., intend to increase the amount of their proposed senior secured term loan to $1.3 billion and not to proceed with their proposed senior secured notes offering. Ocean Rig had previously announced that Drillships Ocean Ventures Inc. and Drillships Ventures Projects Inc. intended to consummate a new $800.0 million senior secured term loan and to concurrently offer $500.0 million in aggregate principal amount of senior secured notes due 2022.

Ocean Rig intends to use the net proceeds from the senior secured term loan, if completed, together with cash on hand, to repay all of the outstanding amounts under its $1.35 billion senior secured term loan facility.

About DryShips DryShips Inc. is an owner of drybulk carriers and tankers that operate worldwide. Through its majority owned subsidiary, Ocean Rig UDW Inc., DryShips owns and operates 13 offshore ultra deepwater drilling units, comprising of 2 ultra deepwater semisubmersible drilling rigs and 11 ultra deepwater drillships, one of which is scheduled to be delivered to the Company during 2015, one of which is scheduled to be delivered during 2016 and 2 of which are scheduled to be delivered during 2017. DryShips owns a fleet of 43 drybulk carriers (including newbuildings), comprising 13 Capesize, 28 Panamax and 2 Supramax, with a combined deadweight tonnage of about 4.6 million tons, and 10 tankers, comprising 6 Suezmax and 4 Aframax, with a combined deadweight tonnage of over 1.3 million tons.

DryShips' common stock is listed on the Nasdaq Global Select Market where it trades under the symbol "DRYS."

The Company's website is at www.dryships.com .

Forward-Looking Statements Matters discussed in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation.

Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words "believe," "intend," "anticipate," "estimate," "project," "forecast," "plan," "potential," "may," "should," "expect" and similar expressions identify forward-looking statements.

The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, general market conditions, including changes in charterhire and drilling dayrates and drybulk vessel, drilling rig and drillship values, failure of a seller to deliver one or more drilling rigs, drillships or drybulk vessels, failure of a buyer to accept delivery of a drilling rig, drillship, or vessel, inability to procure acquisition financing, default by one or more charterers of our ships, changes in demand for drybulk commodities or oil, changes in demand that may affect attitudes of time charterers and customer drilling programs, scheduled and unscheduled drydockings and upgrades, changes in our operating expenses, including bunker prices, drydocking and insurance costs, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, domestic and international political conditions, potential disruption of shipping routes due to accidents and political events or acts by terrorists.

Risks and uncertainties are further described in reports filed by DryShips with the U.S. Securities and Exchange Commission.

Investor Relations / Media: Nicolas Bornozis Capital Link, Inc. (New York) Tel. 212-661-7566 E-mail: dryships@capitallink.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 22

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 27

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Expands Tax Advisory Team with New Experts

Updated Category News Views 199

FTI Consulting Strengthens Tax Advisory Team FTI Consulting, Inc. (NYSE: FCN) has announced the strategic enhancement of its Tax Advisory team within the EMEA region through the recruitment of two highly experienced professionals. This move reflects the company's commitment to providing top-tier advisory services amidst the complexities of the global tax environment. New...

Continue Reading
Cingulate Inc. Unveils Q1 Financial Highlights and Future Plans

Updated Category News Views 148

Cingulate Inc. Reports First Quarter Financial Results Cingulate Inc. (NASDAQ: CING), a biopharmaceutical entity known for its innovative Precision Timed Release™ (PTR™) drug delivery technology, has recently unveiled its financial results for the first quarter. The report sheds light on several important developments concerning their lead assets for ADHD and anxiety....

Continue Reading
Innovative Partnership Propels Sen-Jam Pharmaceutical's Future

Updated Category News Views 106

Strategic Partnership to Enhance Phase 3 Trial for SJP-001 In a significant move, Sen-Jam Pharmaceutical has announced a promising partnership with TASK Clinical, a renowned global contract research organization (CRO), aimed at funding two-thirds of the upcoming Phase 3 clinical trial for its lead candidate, SJP-001. This equity-backed collaboration is not only innovative...

Continue Reading
Exploring the Future of Solar Energy: Insights from EnergySage

Updated Category News Views 231

EnergySage's Solar & Storage Marketplace Report Highlights EnergySage, a trusted name in solar market analysis, has released its latest report, which delves into the current dynamics of the solar and storage marketplace. This comprehensive analysis examines trends that are influencing the future of the industry, particularly in light of recent policy shifts. Residential...

Continue Reading
Investors' Rights: Explore Possible Violations for SCS, HLVX and Others

Updated Category News Views 166

Investigation into Potential Shareholder Violations Halper Sadeh LLC, a well-known law firm advocating for investor rights, is currently investigating several companies due to potential breaches of federal securities laws and fiduciary duties to their shareholders. Steelcase Inc. (SCS) Steelcase Inc. is reportedly undergoing a transaction involving the sale to HNI...

Continue Reading